{"id":451785,"date":"2021-03-05T09:03:34","date_gmt":"2021-03-05T14:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451785"},"modified":"2021-03-05T09:03:34","modified_gmt":"2021-03-05T14:03:34","slug":"tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/","title":{"rendered":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021<\/b><\/p>\n<p class=\"bwalignc\"><i>On-demand presentations scheduled at H.C. Wainwright Global Life Sciences Conference and 33<sup>rd<\/sup> Annual ROTH Conference<\/i><\/p>\n<p class=\"bwalignc\"><i>Live panel discussion scheduled for March 15<sup>th<\/sup> at 12pm ET<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the H.C. Wainwright Global Life Sciences Conference and the 33<sup>rd<\/sup> Annual ROTH Conference, held virtually on March 9-10, 2021, and March 15-17, 2021, respectively.\n<\/p>\n<p>\nGlenn Mattes, President &amp; CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences.\n<\/p>\n<p>\nAdditionally, Dr. Dale Christensen, Director of Clinical Development at TFF Pharmaceuticals, will participate in a panel discussion at the ROTH Conference on March 15<sup>th<\/sup> at 12pm ET. The discussion, titled <i>Therapeutics Against SARS-CoV-2 \u2013 Viral Variants Will Not Fade Away<\/i>, will be led by Dr. Jonathan Aschoff, Managing Director and Senior Research Analyst at ROTH, and Dr. Christensen will be joined by other leading researchers in the industry.\n<\/p>\n<p>\nRecordings of the presentations will be available on-demand to registered conference attendees and can be accessed in the Investor Relations section of the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.tffpharma.com%2F&amp;esheet=52391503&amp;newsitemid=20210305005309&amp;lan=en-US&amp;anchor=TFF+Pharmaceuticals+website&amp;index=1&amp;md5=d94a91f0303215457ba57dd4b6ba360f\">TFF Pharmaceuticals website<\/a>. The Company will also participate in investor and partnering meetings with conference attendees at both events.\n<\/p>\n<p><b>About TFF Pharmaceuticals\u2019 Thin Film Freezing technology platform<\/b><\/p>\n<p>\nTFF Pharmaceuticals\u2019 Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a \u201cBrittle Matrix Particle,\u201d which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.\n<\/p>\n<p><b>About TFF Pharmaceuticals<\/b><\/p>\n<p>\nTFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftffpharma.com&amp;esheet=52391503&amp;newsitemid=20210305005309&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftffpharma.com&amp;index=2&amp;md5=a0867682756fd0e69d7cdeb5d9153223\">https:\/\/tffpharma.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210305005309\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210305005309\/en\/<\/a><\/span><\/p>\n<p>\nGlenn Mattes<br \/>\n<br \/>President and CEO<br \/>\n<br \/>TFF Pharmaceuticals, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gmattes@tffpharma.com\">gmattes@tffpharma.com<br \/>\n<\/a><br \/>737-802-1973\n<\/p>\n<p>\nKirk Coleman<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>TFF Pharmaceuticals, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kcoleman@tffpharma.com\">kcoleman@tffpharma.com<br \/>\n<\/a><br \/>817-989-6358\n<\/p>\n<p><b>Investor Relations and Media:<br \/>\n<\/b><br \/>Paul Sagan<br \/>\n<br \/>LaVoieHealthScience<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:psagan@lavoiehealthscience.com\">psagan@lavoiehealthscience.com<br \/>\n<\/a><br \/>617-865-0041\n<\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Communications Other Health General Health Pharmaceutical Biotechnology Public Relations\/Investor Relations<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210305005309\/en\/757396\/3\/TFF_Pharmaceuticals_Logo_JPEG.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 On-demand presentations scheduled at H.C. Wainwright Global Life Sciences Conference and 33rd Annual ROTH Conference Live panel discussion scheduled for March 15th at 12pm ET AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference, held virtually on March 9-10, 2021, and March 15-17, 2021, respectively. Glenn Mattes, President &amp; CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences. Additionally, Dr. Dale Christensen, Director of Clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 On-demand presentations scheduled at H.C. Wainwright Global Life Sciences Conference and 33rd Annual ROTH Conference Live panel discussion scheduled for March 15th at 12pm ET AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference, held virtually on March 9-10, 2021, and March 15-17, 2021, respectively. Glenn Mattes, President &amp; CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences. Additionally, Dr. Dale Christensen, Director of Clinical &hellip; Continue reading &quot;TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T14:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021\",\"datePublished\":\"2021-03-05T14:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/\"},\"wordCount\":556,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/\",\"name\":\"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-05T14:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/","og_locale":"en_US","og_type":"article","og_title":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk","og_description":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 On-demand presentations scheduled at H.C. Wainwright Global Life Sciences Conference and 33rd Annual ROTH Conference Live panel discussion scheduled for March 15th at 12pm ET AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference, held virtually on March 9-10, 2021, and March 15-17, 2021, respectively. Glenn Mattes, President &amp; CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences. Additionally, Dr. Dale Christensen, Director of Clinical &hellip; Continue reading \"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T14:03:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021","datePublished":"2021-03-05T14:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/"},"wordCount":556,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/","name":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-05T14:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005309r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-to-present-at-virtual-investor-conferences-in-march-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}